Lupus Sci Med:IgG几何平均滴度升高意味着SLE患者的血栓风险增加?

2016-07-07 Mechront 译 MedSci原创

近期有研究表明,系统性红斑狼疮(SLE)患者的IgG抗心磷脂抗体和狼疮抗凝物升高时,患者的血栓形成风险增高。 纽约大学医学院风湿免疫科的Vinicius Domingues博士,和同事对1390例SLE患者进行了研究。根据IgG、IgM和IgA抗心磷脂抗体和狼疮抗凝物将患者分类,比较不同组的患者从诊断SLE时开始的血栓性事件的数量。 数据显示,在随访的17025人年期间发生了284例血

近期有研究表明,系统性红斑狼疮(SLE)患者的IgG抗心磷脂抗体和狼疮抗凝物升高时,患者的血栓形成风险增高。

纽约大学医学院风湿免疫科的Vinicius Domingues博士,和同事对1390例SLE患者进行了研究。根据IgG、IgM和IgA抗心磷脂抗体和狼疮抗凝物将患者分类,比较不同组的患者从诊断SLE时开始的血栓性事件的数量。

数据显示,在随访的17025人年期间发生了284例血栓性事件,发生率为1.7/100人年。研究者发现,IgG抗心磷脂抗体几何平均滴度超过20时,会有较高的血栓形成率(与其他组相比)(RR=1.8)。

此外研究者发现,IgM几何平均滴度的升高与血栓形成之间没有联系(RR=1.2);也没有足够的证据说明IgA几何平均滴度的升高与血栓形成之间有确切的关联(RR=1.7)。

研究表明,系统性红斑狼疮(SLE)患者的IgG抗心磷脂抗体和狼疮抗凝物升高时,患者的血栓形成风险增高。所以研究者也建议在临床实践中,能将这一几何平均滴度指标合理运用。当然,在以后还需要更多更稳健有力的研究来验证该结果。

原始出处:

Domingues V, et al. Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE.Lupus Sci Med. 2016;doi:10.1136/lupus-2015-000107.

Elevated IgG anticardiolipin rate linked with increased risk of thrombotic events in SLE patients.Healio.July 6, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1746453, encodeId=ffcb1e4645385, content=<a href='/topic/show?id=47fd164116e' target=_blank style='color:#2F92EE;'>#SLE患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16411, encryptionId=47fd164116e, topicName=SLE患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41535763769, createdName=wushaoling, createdTime=Mon Aug 22 18:35:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146060, encodeId=94b1146060f9, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 22:35:42 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344955, encodeId=03051344955a2, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606976, encodeId=5f6016069e63f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615177, encodeId=607016151e7f6, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Jul 09 02:35:00 CST 2016, time=2016-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92256, encodeId=d0939225634, content=学习了,可以来探讨, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Thu Jul 07 15:00:00 CST 2016, time=2016-07-07, status=1, ipAttribution=)]
    2016-07-07 明崖

    学习了,可以来探讨

    0

相关资讯

EULAR 2016:系统性红斑狼疮增加女性患宫颈癌的风险

卡罗琳斯卡医学院的Hjalmar Wadström博士和他的同事将研究结果在2016年欧洲风湿病年度会议(EULAR2016)上提出。 在谈到红斑狼疮时,大多数人都认为是系统性红斑狼疮(SLE),因为该病是最常见的疾病类型。系统性红斑狼疮是一种自身免疫性疾病,免疫系统攻击自身的组织和器官,受累部位包括皮肤、关节、大脑、肾脏和血管。根据狼疮研究所的数据显示,美国约有150名系统性红斑狼疮患者,其中超

EULAR 2016:红斑狼疮会增加宫颈癌风险

EULAR年会上称,系统性红斑狼疮(SLE)会增加宫颈癌风险,尤其是使用免疫抑制药物治疗的患者。瑞典卡罗林斯卡学院医学部的Johan Askling博士和同事对4450名SLE女性进行了研究,匹配28113名对照组。其中使用抗疟药的有1783人,其他免疫抑制治疗的有1981人。在随访期间通过瑞典国家宫颈癌筛查注册表和瑞典癌症登记处确定参与者的宫颈非典型增生和浸润性宫颈癌等结局。其他评估结果还包括宫

Nature:LC3相关吞噬过程缺陷或导致全身性红斑狼疮

一项新的研究中,来自美国圣犹大儿童研究医院等机构的研究人员对小鼠大小差异的随机观察,发现一种消化死亡细胞的被称作LC3相关吞噬(LC3-associated phagocytosis, LAP)的过程发生缺陷可能导致一种类似狼疮的自身免疫疾病。相关研究结果于2016年4月20日在线发表在Nature期刊上,论文标题为“Noncanonical autophagy inhibits the au

J Rheumatol:改良Framingham危险因素得分可更好的预测SLE患者冠心病的发生

J Rheumatol:改良Framingham危险因素得分可更好的预测SLE患者冠心病的发生据发表于J Rheumatol的一项新的研究表明,乘以2的改良Framingham危险因素评分可更准确的识别处于冠状动脉疾病高危之中的系统性红斑狼疮患者,并可预测其他冠状动脉疾病事件的发生。研究人员随访了1013名就诊于多伦多大学狼疮门诊的SLE患者,均无冠心病史。分别计算每名患者改良Framingham

系统性红斑狼疮患者何时可以考虑妊娠?

系统性红斑狼疮(SLE)患者必须同时满足下述条件才可以考虑妊娠 1)病情不活动且保持稳定至少6个月; 2)糖皮质激素的使用剂量为泼尼松 15mg/d(或相当剂量)以下; 3)24h尿蛋白排泄定量为0.5克以下; 4)无重要脏器损害; 5)停用免疫抑制药物如环磷酰胺、甲氨蝶呤、雷公藤、霉酚酸酯等至少6个月

Lupus Sci Med:仅靠LSI即可预测SLE的严重性

近期有研究者对俄克拉荷马州医学研究基金会的红斑狼疮家庭注册中心和存储库的1915名系统性红斑狼疮(SLE)的数据进行了分析。他们发现,仅仅依赖于美国风湿病学院(ACR)标准的疾病严重程度指数(LSI)的发展,是SLE活动的可靠指标。研究成果发表在近期的Lupus Sci Med。LSI是基于ACR标准风险评估模型的指标,严重的免疫抑制药物的使用(环磷酰胺、使用霉酚酸酯、环孢菌素或利妥昔单抗)也是疾